• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

作者信息

van Dorp Jeroen, van Montfoort Maurits L, van Dijk Nick, Hofland Ingrid, de Feijter Jeantine M, Bergman Andries M, Hendricksen Kees, van der Poel Henk G, van Rhijn Bas W G, van der Heijden Michiel S

机构信息

Department of Molecular Carcinogenesis, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

出版信息

Clin Genitourin Cancer. 2022 Apr;20(2):e173-e179. doi: 10.1016/j.clgc.2021.12.004. Epub 2021 Dec 10.

DOI:10.1016/j.clgc.2021.12.004
PMID:35016887
Abstract
摘要

相似文献

1
A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.一项关于伊匹木单抗联合纳武单抗用于局限性前列腺癌的意外术前试验。
Clin Genitourin Cancer. 2022 Apr;20(2):e173-e179. doi: 10.1016/j.clgc.2021.12.004. Epub 2021 Dec 10.
2
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.性别与黑色素瘤患者免疫检查点抑制剂治疗结局的相关性。
JAMA Netw Open. 2021 Dec 1;4(12):e2136823. doi: 10.1001/jamanetworkopen.2021.36823.
3
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.在患有原发性或转移灶疾病的黑色素瘤患者中，使用伊匹木单抗和纳武单抗联合进行新辅助免疫治疗。
Br J Dermatol. 2020 Sep;183(3):559-563. doi: 10.1111/bjd.18739. Epub 2019 Dec 26.
4
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.单药或双药免疫检查点抑制剂作为晚期黑色素瘤的辅助治疗
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
5
Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.纳武利尤单抗联合伊匹木单抗与纳武利尤单抗单药治疗对亚洲IV期黑色素瘤患者的真实世界疗效
Eur J Dermatol. 2021 Oct 1;31(5):662-664. doi: 10.1684/ejd.2021.4139.
6
Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.单中心转移性黑色素瘤患者接受伊匹单抗和纳武利尤单抗治疗的临床获益探索性分析。
Clin Transl Oncol. 2022 Feb;24(2):319-330. doi: 10.1007/s12094-021-02692-9. Epub 2021 Aug 22.
7
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.尼妥珠单抗联合西妥昔单抗：免疫治疗恶性黑色素瘤。
Future Oncol. 2019 Feb;15(4):349-358. doi: 10.2217/fon-2018-0607. Epub 2018 Oct 18.
8
Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab.根据单剂量新辅助纳武利尤单抗的病理反应确定的黑色素瘤辅助纳武利尤单抗或伊匹木单抗+纳武利尤单抗治疗
Ann Surg Oncol. 2022 May;29(5):2771-2772. doi: 10.1245/s10434-021-11199-0. Epub 2022 Jan 21.
9
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.OpACIN-neo 研究：新辅助伊匹单抗联合纳武利尤单抗治疗 III 期宏观黑色素瘤的最佳联合剂量方案选择：一项多中心、Ⅱ 期、随机、对照试验
Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.
10
Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.系统评价和荟萃分析抗 PD-1 进展的晚期黑色素瘤患者中免疫检查点抑制剂的疗效和安全性：系统评价和荟萃分析。
Clin Transl Oncol. 2021 Sep;23(9):1885-1904. doi: 10.1007/s12094-021-02598-6. Epub 2021 Apr 20.

引用本文的文献

1
Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.细胞因子白细胞介素-15 与 STING 激动剂 ADU-S100 协同作用，可消除前列腺肿瘤，并在小鼠模型中赋予持久免疫。
Front Immunol. 2023 Jul 3;14:1196829. doi: 10.3389/fimmu.2023.1196829. eCollection 2023.